CA
LGND icon

CWC Advisors’s Ligand Pharmaceuticals LGND Stock Holding History

CWC Advisors’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.03M Sell
3,262
-127
-4% -$29.9K 0.46% 58
2026
Q1 		$677K Sell
3,389
-142
-4% -$28.1K 0.32% 74
2025
Q4 		$668K Sell
3,531
-7
-0.2% -$1.34K 0.32% 72
2025
Q3 		$627K Buy
3,538
+20
+0.6% +$2.97K 0.31% 75
2025
Q2 		$400K Buy
3,518
+88
+3% +$9.41K 0.21% 101
2025
Q1 		$361K Buy
3,430
+821
+31% +$92.8K 0.21% 98
2024
Q4 		$280K Sell
2,609
-43
-2% -$4.86K 0.28% 95
2024
Q3 		$265K Buy
+2,652
New +$267K 0.26% 96

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

CWC Advisors's LGND Position: Q2 2026 in Review

CWC Advisors reduced its Ligand Pharmaceuticals (LGND) stake by 3.7% in Q2 2026, selling an estimated $29.9K and leaving 3,262 shares worth $1.03M. The position accounts for 0.46% of the portfolio, ranked #58.

CWC Advisors first reported a position in LGND in Q3 2024 and has held it in 8 quarters since. 414 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

  • CWC Advisors held 3,262 shares of Ligand Pharmaceuticals worth $1.03M as of Q2 2026.
  • CWC Advisors sold 127 Ligand Pharmaceuticals shares in Q2 2026, an estimated $29.9K.
  • Ligand Pharmaceuticals made up 0.46% of CWC Advisors's portfolio in Q2 2026, its #58 holding.
  • CWC Advisors first reported a position in Ligand Pharmaceuticals in Q3 2024 and has held it in 8 quarters since.
  • 414 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on CWC Advisors's 13F filing for Q2 2026, filed 21 Jul 2026.